Our current results showed that silence of LDB1 could enhance the drug sensitivity of oxaliplatin in CRC cells, and our previous study also showed that overexpression of LDB1 could significantly reduce the drug sensitivity of 5-FU in CRC cells, which further indicated that LDB1 was closely involved in the chemosensitivity of CRC (13). This evidence concerns the gene LDB1 and colorectal carcinoma.